Collegium Pharmaceutical (NASDAQ:COLL) Trading Up 3.8%

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was up 3.8% during mid-day trading on Tuesday . The company traded as high as $38.12 and last traded at $38.12. Approximately 38,601 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 420,141 shares. The stock had previously closed at $36.71.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on COLL shares. Truist Financial increased their price target on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price target on shares of Collegium Pharmaceutical in a research report on Thursday, April 11th. Piper Sandler reissued an “overweight” rating and issued a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. StockNews.com raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 23rd. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $37.00 price objective (up previously from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Collegium Pharmaceutical Stock Performance

The company has a market cap of $1.23 billion, a P/E ratio of 31.11 and a beta of 1.03. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48. The stock’s 50-day moving average price is $37.22 and its 200 day moving average price is $31.47.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. The company had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. As a group, research analysts expect that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of COLL. Pacer Advisors Inc. grew its stake in shares of Collegium Pharmaceutical by 68.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after acquiring an additional 883,380 shares during the last quarter. Penn Capital Management Company LLC acquired a new stake in Collegium Pharmaceutical during the fourth quarter worth $9,755,000. Assenagon Asset Management S.A. boosted its stake in Collegium Pharmaceutical by 178.1% during the third quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock worth $9,513,000 after buying an additional 272,565 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Collegium Pharmaceutical by 1,475.5% during the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock worth $6,190,000 after purchasing an additional 188,347 shares during the last quarter. Finally, Qube Research & Technologies Ltd raised its holdings in Collegium Pharmaceutical by 713.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after purchasing an additional 111,394 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.